Category Researcher Spotlight
Richa Kapoor, PhD
Researcher Spotlight: Richa Kapoor, PhD Perelman School of Medicine, University of Pennsylvania T-cell lymphomas are aggressive cancer types that exhibit clinical and genetic heterogeneity, and current therapies do not incorporate personalized medicine opportunities. Research has shown that cutaneous T-cell lymphoma…
Hannah Isles, PhD
Researcher Spotlight: Hannah Isles, PhD Weill Cornell Medicine Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma (NHL). The recentidentification of DLBCL patient subgroups featuring distinct DNA mutation profiles have provided researchers with new opportunities to treat…
Alexandre Vinaud Hirayama, MD
Researcher Spotlight: Alexandre Vinaud Hirayama, MD Fred Hutchinson Cancer Research Center Chimeric antigen receptor (CAR) T cell therapy is a typeof immunotherapy that genetically modifies a patient’simmune cells to recognize and kill tumor cells. “CAR T cell therapy has shown…
Rui Guo, PhD
Researcher Spotlight: Rui Guo, PhD Brigham and Women’s Hospital, Harvard Medical School Epstein-Barr virus (EBV) was the first virus found to causeBurkitt lymphoma, a rare and aggressive form of non-Hodgkin lymphoma (NHL). The virus shuts down nearlyall its genes in…
Edmond Feris, PhD
Researcher Spotlight: Edmond Feris, PhD Dartmouth-Hitchcock Norris Cotton Cancer Center Some of the most critical oncogenes responsible fortumor formation in humans are transcription factors. Dr.Feris’ LRF research project focuses on the study of howtranscriptional dysregulation can lead to carcinogenesis(the process…
Lydie Debaize, PhD
Researcher Spotlight: Lydie Debaize, PhD Dana-Farber Cancer Institute Most patients treated for mantle cell lymphoma (MCL)achieve complete remission. Nevertheless, a significantnumber of patients will eventually relapse due to theregrowing of rare cancer cells remaining in the bodyafter treatment, which is known…
Kathleen Dixon, PhD
Researcher Spotlight: Kathleen Dixon, PhD University of Minnesota Twin Cities The pioneer monoclonal antibody therapy rituximab(Rituxan) has revolutionized the treatment of B-cell lymphomas. However, patient response to rituximab varies based on numerous factors, including the affinity with which immune cells…
Elena Battistello, PhD
Researcher Spotlight: Elena Battistello, PhD New York University School of Medicine Peripheral T-cell lymphoma (PTCL) is an aggressive type of non-Hodgkin lymphoma (NHL) derived from the malignant transformation of blood cells called T-lymphocytes. Currently, patients diagnosed with PTCL have limited…
Marco Ruella, MD
Researcher Spotlight: Marco Ruella, MD Perelman School of Medicine, University of Pennsylvania Chimeric antigen receptor (CAR) T cell therapy has been very successful in certain cancers, such as B-cell leukemia and lymphoma. However, the needle has not moved for most…